Alzamend Neuro says Massachusetts General ends AL001 bipolar disorder trial agreement
ALZN•
ALZN•Massachusetts General Hospital terminated its agreement with Alzamend Neuro for the AL001 Phase II bipolar disorder trial on November 11, 2026, following a pause. The company plans to discuss moving directly to Phase III with the FDA, whose feedback is expected by the end of the second quarter of 2027.
Massachusetts General Hospital terminated its agreement with Alzamend Neuro for the AL001 Phase II bipolar disorder trial on November 11, 2026, following a pause. FDA feedback on October 15 questioned whether the planned trials could provide sufficient evidence of effectiveness to support a drug application. Alzamend Neuro’s proposed revised plan would end Phase II trials and move directly to Phase III in bipolar disorder; feedback on that strategy is expected by the end of the second quarter of 2027. The completed healthy-subject trial remains unaffected, with final results scheduled for release in December 2026.